
  
    
      
        Introduction_NNP
        NO_DT ,_, which_WDT may_MD be_VB synthesized_JJ by_IN any_DT of_IN the_DT three_CD
        isoforms_NNS of_IN NOS_NNP ,_, is_VBZ a_DT vasodilator_NN of_IN the_DT pulmonary_JJ
        circulation_NN in_IN many_JJ mammals_NNS ._. NO_DT has_VBZ been_VBN proposed_VBN as_IN a_DT
        modulator_NN of_IN vascular_NN tone_NN and_CC structure_NN in_IN the_DT pulmonary_JJ
        circulation_NN ,_, and_CC previous_JJ studies_NNS using_VBG NOS_NNP inhibitors_NNS [_NN 1_CD ,_,
        2_CD ]_NN suggested_VBD that_DT inhibition_NN of_IN NO_DT increases_NNS acute_JJ hypoxic_JJ
        pulmonary_JJ vasoconstriction_NN ._. Chronic_NNP NOS_NNP inhibition_NN did_VBD not_RB
        lead_VB to_TO development_NN of_IN pulmonary_JJ hypertension_NN [_NN 3_CD ]_NN ,_,
        however_RB ,_, possibly_RB because_IN of_IN a_DT decrease_NN in_IN cardiac_JJ output_NN ._.
        These_DT discrepancies_NNS have_VBP been_VBN addressed_VBN in_IN recent_JJ studies_NNS
        using_VBG mice_NNS that_WDT are_VBP deficient_NN in_IN NOS_NNP isoforms_NNS ._.
        Three_CD isoforms_NNS of_IN NOS_NNP are_VBP found_VBN in_IN the_DT lung_NN ._. The_DT
        principle_NN isoform_NN that_WDT is_VBZ found_VBN in_IN the_DT pulmonary_JJ
        vasculature_NN is_VBZ eNOS_NN [_NN 4_CD ]_NN ._. iNOS_NN is_VBZ expressed_VBN in_IN airway_NN
        epithelium_NN ,_, and_CC airway_NN and_CC vascular_NN smooth_JJ muscle_NN [_NN 5_CD ,_, 6_CD ]_NN ,_,
        whereas_IN nNOS_NN is_VBZ expressed_VBN in_IN the_DT bronchial_NN epithelium_NN and_CC
        lung_NN nervous_JJ tissue_NN [_NN 4_CD ,_, 5_CD ,_, 7_CD ,_, 8_CD ]_NN ._. Thus_RB ,_, all_DT three_CD NOS_NNP
        isoforms_NNS could_MD contribute_VB to_TO modulation_NN of_IN pulmonary_JJ
        vascular_NN tone_NN ._. Studies_NNS using_VBG knockout_NN mice_NNS for_IN each_DT of_IN
        these_DT isoforms_NNS [_NN 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ]_NN suggest_VBP that_IN eNOS-derived_JJ
        NO_DT is_VBZ important_JJ in_IN modulating_VBG basal_NN pulmonary_JJ vascular_NN
        tone_NN ,_, as_RB well_RB as_IN in_IN attenuating_VBG the_DT development_NN of_IN
        pulmonary_JJ hypertension_NN ._.
        Severe_NNP sustained_VBD hypoxia_NN causes_NNS pulmonary_JJ hypertension_NN
        in_IN many_JJ animals_NNS ._. Upregulation_NNP of_IN all_DT three_CD NOS_NNP isoforms_NNS
        following_VBG severe_JJ hypoxia_NN has_VBZ been_VBN reported_VBN in_IN rats_NNS [_NN 4_CD ,_, 13_CD ,_,
        14_CD ,_, 15_CD ,_, 16_CD ]_NN ._. Less_RBR is_VBZ certain_JJ about_IN the_DT expression_NN of_IN NOS_NNP in_IN
        the_DT murine_NN lung_NN following_VBG hypoxia_NN ,_, with_IN previous_JJ reports_NNS [_NN
        17_CD ,_, 18_CD ]_NN suggesting_VBG an_DT increase_NN in_IN lung_NN eNOS_NN and_CC iNOS_NN
        levels_NNS ._. We_PRP therefore_RB hypothesized_VBN that_IN NOS_NNP isoforms_NNS are_VBP
        upregulated_JJ following_NN hypoxia_NN and_CC that_IN this_DT may_MD account_VB for_IN
        the_DT increased_VBN susceptibility_NN to_TO hypoxic_JJ pulmonary_JJ
        hypertension_NN in_IN mice_NNS that_WDT lack_NN eNOS_NN [_NN 9_CD ,_, 12_CD ]_NN ._. In_IN the_DT
        present_JJ study_NN we_PRP exposed_VBD wild-type_JJ mice_NNS to_TO severe_JJ hypobaric_JJ
        hypoxia_NN from_IN birth_NN and_CC measured_VBN NOS_NNP mRNA_NN and_CC protein_NN
        levels_NNS ._. We_PRP then_RB compared_VBD the_DT findings_NNS with_IN localization_NN of_IN
        NOS_NNP protein_NN in_IN the_DT lung_NN as_IN assessed_VBN using_VBG
        immunohistochemistry_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Mice_NNS
          We_PRP studied_VBD F_NN 1_CD -_: generation_NN SV_NNP 129_CD (_( Taconic_NNP ,_, Germantown_NNP ,_,
          NY_NNP ,_, USA_NNP )_) and_CC C_NNP 57_CD BL_NNP /_NN 6_CD (_( Jackson_NNP Laboratories_NNPS ,_, Bar_NNP Harbor_NNP ,_,
          ME_NNP ,_, USA_NNP )_) mice_NNS at_IN age_NN 6_CD weeks_NNS ._.
        
        
          Exposure_NNP environments_NNS
          Within_IN 24_CD -_: 36_CD h_NN of_IN birth_NN ,_, pups_NNS and_CC dam_NN were_VBD placed_VBN in_IN
          ambient_NN conditions_NNS ,_, hypobaric_JJ hypoxia_NN (_( simulating_VBG an_DT
          altitude_NN of_IN 17_CD ,_, 000_CD feet_NNS )_) ,_, or_CC hyberbaric_JJ normoxia_NN
          (_( simulating_VBG sea_NN level_NN )_) ._. Exposure_NNP was_VBD continuous_JJ ,_, with_IN
          minimal_JJ interruption_NN for_IN animal_NN care_NN ._. At_IN 21_CD days_NNS the_DT dam_NN
          was_VBD removed_VBN and_CC animals_NNS were_VBD sorted_VBN by_IN sex_NN ._. At_IN 6_CD weeks_NNS
          animals_NNS of_IN both_DT sexes_NNS were_VBD removed_VBN for_IN study_NN ._.
        
        
          Right_RB ventricular_NN pressure_NN measurements_NNS
          RVsP_NNP was_VBD measured_VBN as_RB previously_RB described_VBD [_NN 9_CD ]_NN ._.
          Briefly_NNP ,_, mice_NNS were_VBD anesthetized_JJ with_IN ketamine_NN /_NN xyalazine_NN
          (_( 100_CD /_NN 15_CD mg_NN /_NN kg_NN )_) ,_, placed_VBN supine_NN while_IN spontaneously_RB
          breathing_VBG room_NN air_NN ,_, and_CC a_DT 26_CD -_: gauge_VB needle_NN was_VBD introduced_VBN
          percutaneously_RB into_IN the_DT thorax_NN via_IN a_DT subxyphloid_NN
          approach_NN ;_: RVsP_NNP was_VBD recorded_VBN ._. Blood_NNP was_VBD drawn_VBN and_CC animals_NNS
          were_VBD killed_VBN ._. The_DT thorax_NN was_VBD opened_VBN and_CC the_DT lungs_NNS were_VBD
          flushed_JJ with_IN cold_JJ PBS_NNP ._. The_DT right_JJ lung_NN was_VBD frozen_VBN for_IN
          protein_NN and_CC RNA_NNP measurement_NN ,_, and_CC the_DT left_NN lung_NN was_VBD fixed_VBN
          for_IN histologic_JJ evaluation_NN ._.
        
        
          Western_NNP blotting_VBG
          Frozen_NNP lung_NN tissue_NN was_VBD homogenized_JJ in_IN ice_NN cold_JJ 750_CD μl_NN
          radioimmunoprecipitation_NN assay_NN (_( RIPA_NNP )_) buffer_NN (_( 1_CD ×_NN PBS_NNP ,_, 1_CD %_NN
          Igepal_NNP CA-_NNP 630_CD ,_, 0_CD ._. 5_CD %_NN sodium_NN deoxycholate_NN ,_, 0_CD ._. 1_CD %_NN SDS_NNP )_) plus_CC
          protease_NN inhibitors_NNS (_( 30_CD μl_NN /_NN ml_NN RIPA_NNP aprotinin_NN ,_, 10_CD μl_NN /_NN ml_NN
          RIPA_NNP 100_CD mmol_NN /_NN l_NN sodium_NN orthovanadate_NN )_) ._. Samples_NNP were_VBD
          triturated_JJ two_CD to_TO three_CD times_NNS through_IN 21_CD -_: gauge_VB then_RB
          25_CD -_: gauge_VB needles_NNS ,_, and_CC 10_CD μl_NN /_NN ml_NN RIPA_NNP 10_CD mg_NN /_NN ml_NN phenyl_NN
          methylsulfonyl_NN fluoride_NN was_VBD added_VBN ._. Samples_NNP were_VBD
          centrifuged_JJ twice_RB at_IN 4_CD °_NN C_NNP and_CC 14_CD ,_, 000_CD rpm_NN ._. Protein_NNP
          concentration_NN was_VBD determined_VBN using_VBG the_DT Bradford_NNP method_NN
          (_( Bio-_NNP Rad_NNP Laboratories_NNPS ,_, Hercules_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Protein_NNP 10_CD μg_NN
          (_( eNOS_NN )_) or_CC 80_CD μg_NN (_( nNOS_NN and_CC iNOS_NN )_) were_VBD separated_VBN by_IN
          SDS-PAGE_NNP under_IN reducing_VBG conditions_NNS (_( 1_CD %_NN β-mercaptoethanol_JJ )_)
          using_VBG 8_CD -_: 16_CD %_NN gradient_NN gels_NNS (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP ,_,
          USA_NNP )_) ._. Coomassie_NNP blue_JJ staining_VBG was_VBD used_VBN to_TO verify_VB equal_JJ
          loading_NN of_IN gel_NN ._. Gels_NNP were_VBD transferred_VBN in_IN 20_CD %_NN methanol_NN to_TO
          polyvinylidene_NN difluoride_NN membrane_NN (_( Amersham_NNP Pharmacia_NNP
          Biotech_NNP ,_, Piscataway_NNP ,_, NJ_NNP ,_, USA_NNP )_) ._. Blots_NNP were_VBD blocked_VBN (_( 0_CD ._. 5_LS %_NN
          Tween_NNP 20_CD ,_, 1_CD %_NN milk_NN )_) and_CC incubated_JJ with_IN primary_JJ antibody_NN
          for_IN 45_CD min_NN at_IN 37_CD °_NN C_NNP (_( 1_CD :_: 1500_CD anti-e_JJ NOS_NNP mono_NN [_NN BD_NNP
          Transduction_NNP Laboratories_NNPS ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP ]_NN ;_: 1_CD :_: 1500_CD
          anti-n_JJ NOS_NNP poly_RB [_NN Zymed_NNP Laboratories_NNPS ,_, South_NNP San_NNP Francisco_NNP ,_,
          CA_NNP ,_, USA_NNP ]_NN ;_: 1_CD :_: 200_CD anti-i_JJ NOS_NNP poly_RB [_NN Affinity_NNP Bioreagents_NNP ,_,
          Golden_NNP ,_, CO_NNP ,_, USA_NNP ]_NN ;_: and_CC 1_CD :_: 1500_CD anti-β-actin_JJ mono_NN [_NN Sigma_NNP
          A_DT 5441_CD ;_: Sigma-_NNP Aldrich_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP ]_NN )_) ._. Blots_NNP were_VBD
          washed_VBN and_CC incubated_JJ with_IN secondary_JJ antibody_NN (_( 1_CD :_: 1500_CD
          horseradish_NN peroxidase_NN )_) conjugated_JJ antimouse_NN (_( eNOS_NN )_) or_CC
          antirabbit_NN (_( nNOS_NN ,_, iNOS_NN ,_, and_CC β-actin_JJ )_) for_IN 45_CD min_NN at_IN 37_CD °_NN C_NNP ._.
          Blots_NNP were_VBD developed_VBN with_IN Enhanced_NNP Chemiluminescence_NNP
          (_( Amersham_NNP Pharmacia_NNP Biotech_NNP )_) ._. INOS-positive_NNP control_NN was_VBD
          lipopolysaccharide-treated_JJ mouse_NN spleen_NN protein_NN and_CC
          nNOS-positive_JJ control_NN was_VBD mouse_NN brain_NN protein_NN ._.
        
        
          Quantitative_NNP reverse-transcription_JJ polymerase_NN chain_NN
          reaction_NN
          Total_NNP RNA_NNP was_VBD extracted_VBN from_IN 100_CD mg_NN of_IN frozen_VBN lung_NN
          using_VBG Tri-reagent_NNP (_( Molecular_NNP Research_NNP Center_NNP ,_, Inc_NNP ._. ,_,
          Cincinnati_NNP ,_, OH_NNP ,_, USA_NNP )_) and_CC the_DT final_JJ product_NN was_VBD
          resuspended_JJ in_IN 20_CD μl_NN diethylpyro_NN carbonate_NN depC_NN H_NNP 
          2_CD O_NNP ._. RNA_NNP was_VBD quantified_VBN and_CC samples_NNS
          with_IN A_DT 
          260_CD /_NN A_DT 
          280_CD >_NN 1_CD ._. 8_CD were_VBD used_VBN ._. Samples_NNP were_VBD
          diluted_VBN in_IN depC_NN H_NNP 
          2_CD O_NNP and_CC 50_CD ng_NN were_VBD used_VBN in_IN
          quantitative_JJ one-tube_JJ reverse-transcription_JJ PCR_NNP (_( Applied_NNP
          Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. RNA_NNP quantity_NN was_VBD
          determined_VBN using_VBG 18_CD S_NNP rRNA_NN primers_NNS /_NN probes_NNS (_( Applied_NNP
          Biosystems_NNP )_) and_CC eNOS_NN ,_, iNOS_NN and_CC nNOS_NN expression_NN determined_VBD
          using_VBG the_DT primer_NN /_NN probe_NN sequences_NNS shown_VBN in_IN Table_NNP 1_CD ._.
          Message_NNP abundance_NN was_VBD determined_VBN by_IN dividing_VBG the_DT quantity_NN
          of_IN message_NN of_IN interest_NN by_IN the_DT quantity_NN of_IN 18_CD S_NNP ribosomal_JJ
          RNA_NNP ._.
        
        
          Immunohistochemistry_NNP
          Left_NNP lungs_NNS were_VBD inflated_VBN with_IN 1_CD %_NN agarose_NN ,_, fixed_VBN in_IN
          methyl_NN carnoys_NNS (_( 60_CD %_NN methanol_NN ,_, 30_CD %_NN chloroform_NN and_CC 10_CD %_NN
          glacial_JJ acetic_JJ acid_NN )_) ,_, embedded_VBN in_IN paraffin_NN ,_, and_CC
          sectioned_JJ ._. Sections_NNP were_VBD stained_JJ with_IN anti-_NN NOS_NNP antibodies_NNS
          (_( eNOS_NN ,_, BD_NNP Transduction_NNP Laboratories_NNPS N_NNP 30020_CD ,_, 1_CD :_: 400_CD
          dilution_NN ;_: iNOS_NN ,_, Zymed_NNP Laboratories_NNPS 61_CD -_: 7000_CD ,_, 1_CD :_: 1000_CD
          dilution_NN ;_: nNOS_NN ,_, Transduction_NNP N_NNP 32030_CD ,_, 1_CD :_: 500_CD dilution_NN )_) ,_,
          developed_VBN with_IN 3_CD ,_, 3_CD '_POS -_: diaminobenzidine_NN ,_, and_CC counterstained_JJ
          with_IN hematoxylin_NN ._.
        
        
          Hematocrit_NNP and_CC nitric_JJ oxide_NN metabolite_NN
          measurements_NNS
          Heparinized_NNP blood_NN 100_CD μl_NN was_VBD placed_VBN in_IN capillary_JJ tubes_NNS
          and_CC hematocrit_NN determined_VBN by_IN standard_JJ techniques_NNS [_NN 9_CD ]_NN ._.
          The_DT remainder_NN of_IN the_DT blood_NN was_VBD spun_VBN at_IN 4000_CD rpm_NN for_IN 10_CD
          min_NN ,_, and_CC plasma_NN removed_VBN and_CC frozen_VBN ._. Later_RB ,_, samples_NNS were_VBD
          thawed_JJ and_CC centrifuged_JJ at_IN 15_CD ,_, 000_CD rpm_NN for_IN 20_CD min_NN ._. Plasma_NNP
          NO_DT metabolites_NNS (_( NO_DT ,_, NO_DT 
          2_CD -_: ,_, NO_DT 
          3_CD -_: ,_, peroxynitrate_NN ,_, and_CC nitrosothiols_NNS )_)
          were_VBD measured_VBN using_VBG a_DT NO_DT chemiluminescence_NN analyzer_NN
          (_( Ionics_NNP Instrument_NNP Business_NNP Group_NNP ,_, Boulder_NNP ,_, CO_NNP ,_, USA_NNP )_) ._.
          Plasma_NNP samples_NNS 1_CD μl_NN were_VBD added_VBN to_TO 2_CD ml_NN vanadium_NN III_NNP
          chloride_NN (_( Sigma-_NNP Aldrich_NNP )_) dissolved_VBN in_IN 1_CD N_NNP HCl_NNP at_IN 90_CD °_NN C_NNP to_TO
          reduce_VB all_DT NO_DT metabolites_NNS to_TO NO_DT ._. NO_DT was_VBD driven_VBN into_IN the_DT
          chemiluminescence_NN detector_NN by_IN bubbling_VBG with_IN argon_NN ._.
        
        
          Statistical_NNP analysis_NN
          Data_NNP are_VBP expressed_VBN as_IN mean_NN ±_NN standard_JJ error_NN of_IN the_DT
          mean_NN ._. Data_NNP were_VBD analyzed_VBN using_VBG analysis_NN of_IN variance_NN ,_, and_CC 
          P_NN <_NN 0_CD ._. 05_CD is_VBZ considered_VBN
          statistically_RB significant_JJ ._.
        
      
      
        Results_NNS
        
          Measurements_NNP of_IN pulmonary_JJ hypertension_NN
          RVsP_NNP was_VBD measured_VBN as_IN an_DT index_NN of_IN pulmonary_JJ arterial_NN
          pressure_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 1_LS ,_, RVsP_NNP was_VBD elevated_VBD in_IN
          animals_NNS that_WDT were_VBD exposed_VBN to_TO hypobaric_JJ hypoxia_NN as_IN
          compared_VBN with_IN those_DT that_WDT were_VBD exposed_VBN to_TO sea_NN level_NN and_CC
          ambient_NN conditions_NNS ._. Hypoxic_NNP animals_NNS were_VBD also_RB more_RBR
          polycythemic_JJ than_IN were_VBD normoxic_JJ animals_NNS (_( 70_CD %_NN ±_NN 4_CD %_NN in_IN
          hypoxic_JJ animals_NNS versus_CC 45_CD %_NN ±_NN 3_CD %_NN and_CC 42_CD %_NN ±_NN 3_CD %_NN for_IN animal_NN
          subjected_VBN to_TO sea_NN level_NN and_CC ambient_NN conditions_NNS ,_,
          respectively_RB ;_: 
          P_NN <_NN 0_CD ._. 001_CD )_) ._.
        
        
          Western_NNP blotting_VBG
          As_IN shown_VBN in_IN Fig_NNP ._. 2_LS ,_, lung_NN eNOS_NN protein_NN levels_NNS were_VBD
          increased_VBN following_VBG hypoxia_NN ,_, with_IN a_DT trend_NN toward_IN
          increased_VBN eNOS_NN in_IN ambient_NN versus_CC sea_NN level_NN conditions_NNS ._.
          However_RB ,_, iNOS_NN protein_NN was_VBD below_IN the_DT limit_NN of_IN detection_NN
          following_VBG any_DT level_NN of_IN hypoxic_JJ exposure_NN (_( positive_JJ control_NN
          was_VBD lipopolysaccharide-treated_JJ mouse_NN spleen_NN )_) and_CC using_VBG
          several_JJ different_JJ antibodies_NNS (_( Affinity_NNP Bioreagents_NNP and_CC BD_NNP
          Transduction_NNP Laboratories_NNPS ;_: Affinity_NNP Bioreagents_NNP blot_NN
          shown_VBN )_) ,_, and_CC nNOS_NN was_VBD unchanged_JJ among_IN the_DT three_CD
          experimental_JJ groups_NNS (_( positive_JJ control_NN was_VBD mouse_NN
          brain_NN )_) ._.
        
        
          Quantitative_NNP reverse-transcription_JJ polymerase_NN chain_NN
          reaction_NN
          eNOS_NN expression_NN in_IN the_DT lung_NN ,_, as_IN studied_VBN using_VBG
          quantitative_JJ reverse-transcription_JJ PCR_NNP ,_, was_VBD increased_VBD
          1_CD ._. 5_CD -_: fold_VB following_VBG hypoxia_NN as_IN compared_VBN with_IN normoxic_JJ
          conditions_NNS ,_, whereas_IN iNOS_NN expression_NN was_VBD increased_VBD
          3_CD ._. 5_CD -_: fold_VB (_( Fig_NNP ._. 3_LS )_) ._.
        
        
          Immunohistochemistry_NNP
          Localization_NNP of_IN NOS_NNP in_IN mouse_NN lung_NN was_VBD determined_VBN using_VBG
          antibodies_NNS specific_JJ for_IN eNOS_NN ,_, iNOS_NN ,_, and_CC nNOS_NN (_( Fig_NNP ._. 4_LS )_) ._.
          eNOS_NN levels_NNS were_VBD increased_VBN following_VBG hypoxia_NN ,_, and_CC the_DT
          staining_VBG was_VBD more_RBR intense_JJ in_IN large_JJ vessels_NNS and_CC extended_VBN
          out_IN to_TO the_DT periphery_NN of_IN the_DT lung_NN ,_, and_CC was_VBD also_RB found_VBN in_IN
          smaller_JJR vessels_NNS ._. In_IN contrast_NN ,_, iNOS_NN and_CC nNOS_NN were_VBD limited_JJ
          primarily_RB to_TO the_DT airway_NN epithelium_NN ,_, and_CC their_PRP$ levels_NNS did_VBD
          not_RB increase_VB following_VBG exposure_NN to_TO hypoxia_NN ._. This_DT was_VBD
          confirmed_VBN using_VBG quantitative_JJ image_NN analysis_NN (_( data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Nitric_NNP oxide_NN metabolites_NNS
          To_TO determine_VB whether_IN the_DT increase_NN in_IN NOS_NNP in_IN the_DT
          pulmonary_JJ circulation_NN following_VBG hypoxia_NN resulted_VBD in_IN
          increased_VBD NO_DT ,_, we_PRP measured_VBD plasma_NN NO_DT metabolites_NNS (_( Fig_NNP ._. 5_LS )_) ._.
          There_EX was_VBD a_DT modest_JJ increase_NN in_IN levels_NNS of_IN NO_DT metabolites_NNS
          in_IN animals_NNS exposed_VBN to_TO hypoxia_NN as_IN compared_VBN with_IN sea_NN level_NN
          or_CC ambient_NN conditions_NNS ._.
        
      
      
        Discussion_NNP
        The_DT major_JJ finding_NN of_IN this_DT work_NN was_VBD the_DT upregulation_NN of_IN
        lung_NN expression_NN of_IN eNOS_NN and_CC possibly_RB iNOS_NN in_IN mice_NNS with_IN
        severe_JJ hypoxia-induced_JJ pulmonary_JJ hypertension_NN ._. The_DT
        increased_VBN eNOS_NN was_VBD correlated_JJ with_IN increased_VBN
        immunolocalization_NN to_TO the_DT periphery_NN of_IN the_DT lung_NN ._. This_DT ,_,
        however_RB ,_, was_VBD not_RB observed_VBN for_IN iNOS_NN or_CC nNOS_NN ._. Additionally_RB ,_,
        we_PRP found_VBD increased_VBN severity_NN of_IN pulmonary_JJ hypertension_NN in_IN
        animals_NNS exposed_VBN to_TO hypoxia_NN during_IN postnatal_NN
        development_NN ._.
        The_DT pulmonary_JJ hypertension_NN in_IN mice_NNS exposed_VBN to_TO hypoxia_NN
        from_IN birth_NN was_VBD more_RBR severe_JJ than_IN we_PRP had_VBD observed_VBN in_IN previous_JJ
        studies_NNS of_IN 4_CD weeks_NNS of_IN hypoxia_NN in_IN mature_VBP animals_NNS [_NN 9_CD ]_NN ._. The_DT
        degree_NN of_IN polycythemia_NN was_VBD also_RB greater_JJR in_IN these_DT animals_NNS
        than_IN in_IN previous_JJ reports_NNS ,_, and_CC might_MD have_VB contributed_VBN to_TO the_DT
        increase_NN in_IN pulmonary_JJ pressure_NN due_JJ to_TO increased_VB viscosity_NN [_NN
        19_CD ]_NN ._. This_DT suggests_VBZ that_IN either_DT the_DT duration_NN of_IN hypoxic_JJ
        exposure_NN or_CC exposure_NN from_IN neonatal_NN life_NN provided_VBD additional_JJ
        physiologic_JJ stress_NN that_WDT was_VBD not_RB seen_VBN in_IN more_JJR mature_VBP animals_NNS
        [_NN 9_CD ]_NN ._. No_DT animals_NNS died_VBD ,_, however_RB ,_, suggesting_VBG that_IN the_DT stress_NN
        was_VBD not_RB sufficiently_RB severe_JJ to_TO decrease_VB survival_NN during_IN the_DT
        study_NN period_NN ._. This_DT observation_NN of_IN increased_VBN susceptibility_NN
        to_TO hypoxic_JJ pulmonary_JJ hypertension_NN in_IN younger_JJR ,_, developing_VBG
        animals_NNS is_VBZ in_IN agreement_NN with_IN previous_JJ reports_NNS [_NN 20_CD ,_,
        21_CD ]_NN ._.
        The_DT increase_NN in_IN eNOS_NN protein_NN and_CC mRNA_NN levels_NNS ,_, and_CC the_DT
        peripheral_JJ immunolocalization_NN is_VBZ in_IN accord_NN with_IN previous_JJ
        reports_NNS [_NN 13_CD ,_, 14_CD ,_, 18_CD ]_NN ._. LeCras_NNP 
        et_CC al_NN ._. [_NN 13_CD ]_NN found_VBD that_IN the_DT amount_NN
        of_IN eNOS_NN protein_NN was_VBD increased_VBN in_IN hypoxic_JJ ,_, hypertensive_JJ rat_NN
        lungs_NNS ,_, and_CC that_IN this_DT was_VBD not_RB entirely_RB due_JJ to_TO the_DT presence_NN
        of_IN hypertension_NN and_CC increased_VBN shear_NN stress_NN ,_, but_CC was_VBD also_RB
        due_JJ to_TO hypoxia_NN ._. This_DT is_VBZ further_RBR supported_VBN by_IN Tyler_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN ,_, who_WP found_VBD that_DT eNOS_NN
        protein_NN levels_NNS were_VBD increased_VBN in_IN rats_NNS with_IN hypoxic_JJ
        pulmonary_JJ hypertension_NN but_CC not_RB in_IN those_DT with_IN
        chemical-induced_JJ (_( monocrotaline_NN )_) or_CC genetic_JJ (_( fawn-hooded_JJ
        rat_NN )_) pulmonary_JJ hypertension_NN [_NN 15_CD ]_NN ._. As_IN in_IN the_DT present_JJ study_NN ,_,
        increased_VBN eNOS_NN levels_NNS correlated_JJ with_IN 
        de_IN novo_NN expression_NN in_IN the_DT small_JJ
        resistance_NN vessels_NNS in_IN the_DT lung_NN [_NN 14_CD ,_, 18_CD ]_NN ._. The_DT mechanism_NN by_IN
        which_WDT hypoxia_NN increases_NNS eNOS_NN expression_NN is_VBZ poorly_RB
        understood_VBN because_IN a_DT hypoxia_NN responsive_JJ element_NN has_VBZ not_RB yet_RB
        been_VBN identified_VBN in_IN the_DT eNOS_NN promoter_NN ._. Recently_RB ,_, altering_VBG
        the_DT redox_NN state_NN of_IN pulmonary_JJ artery_NN endothelial_NN cells_NNS in_IN
        culture_NN suggested_VBD that_DT activation_NN of_IN redox-sensitive_JJ
        transcription_NN factor_NN activator_NN protein-_NN 1_CD during_IN hypoxia_NN may_MD
        be_VB responsible_JJ for_IN the_DT increase_NN in_IN eNOS_NN expression_NN [_NN 22_CD ]_NN ._.
        Despite_IN the_DT increase_NN in_IN eNOS_NN ,_, however_RB ,_, the_DT mice_NNS developed_VBD
        severe_JJ pulmonary_JJ hypertension_NN ;_: this_DT suggests_VBZ either_CC that_IN NO_DT
        production_NN was_VBD not_RB increased_VBN (_( see_VB below_IN )_) or_CC that_IN NO_DT was_VBD
        consumed_VBN ._. Under_IN more_RBR physiologically_RB relevant_JJ levels_NNS of_IN
        hypoxia_NN ,_, the_DT central_JJ role_NN of_IN eNOS_NN in_IN protecting_VBG against_IN
        hypertension_NN is_VBZ supported_VBN by_IN our_PRP$ observation_NN that_DT loss_NN of_IN
        eNOS_NN leads_VBZ to_TO increased_VB acute_JJ hypoxic_JJ vasoconstriction_NN and_CC
        development_NN of_IN pulmonary_JJ hypertension_NN [_NN 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ]_NN ._.
        In_IN contrast_NN to_TO the_DT observations_NNS with_IN eNOS_NN ,_, iNOS_NN message_NN
        was_VBD increased_VBN but_CC iNOS_NN protein_NN remained_VBD below_IN the_DT limit_NN of_IN
        detection_NN in_IN the_DT lungs_NNS of_IN hypoxic_JJ ,_, hypertensive_JJ mice_NNS ._.
        Previously_RB ,_, LeCras_NNP 
        et_CC al_NN ._. [_NN 14_CD ]_NN reported_VBD an_DT increase_NN in_IN
        both_DT iNOS_NN mRNA_NN and_CC protein_NN levels_NNS in_IN rat_NN lungs_NNS following_VBG
        hypoxia_NN ._. In_IN the_DT present_JJ study_NN ,_, however_RB ,_, the_DT increase_NN in_IN
        iNOS_NN mRNA_NN levels_NNS was_VBD not_RB associated_VBN with_IN detectable_JJ iNOS_NN
        protein_NN ,_, using_VBG several_JJ different_JJ antibodies_NNS ,_, in_IN mice_NNS ._. This_DT
        is_VBZ in_IN contrast_NN to_TO the_DT study_NN of_IN Quinlan_NNP 
        et_CC al_NN ._. [_NN 17_CD ]_NN ,_, in_IN which_WDT increased_VBD lung_NN
        iNOS_NN protein_NN levels_NNS in_IN adult_NN mice_NNS following_VBG hypoxia_NN was_VBD
        reported_VBN ._. This_DT discrepancy_NN may_MD be_VB due_JJ to_TO differences_NNS
        between_IN the_DT present_JJ study_NN and_CC that_DT report_NN ._. Specifically_RB ,_,
        animals_NNS in_IN our_PRP$ experiments_NNS are_VBP a_DT different_JJ strain_NN and_CC were_VBD
        housed_VBN in_IN sealed_VBN hypobaric_JJ chambers_NNS as_IN opposed_VBN to_TO being_VBG
        flushed_JJ with_IN 10_CD %_NN O_NNP 
        2_CD gas_NN ._. The_DT hypobaric_JJ chambers_NNS used_VBN in_IN
        the_DT present_JJ study_NN have_VBP a_DT higher_JJR rate_NN of_IN air_NN exchange_NN than_IN
        other_JJ hypoxic_JJ gas_NN chambers_NNS ,_, thus_RB limiting_VBG the_DT build-up_NN of_IN
        waste_NN products_NNS ,_, including_VBG ammonia_NN ,_, that_WDT may_MD contribute_VB to_TO
        lung_NN inflammation_NN and_CC induction_NN of_IN iNOS_NN ,_, as_IN the_DT combination_NN
        of_IN hypoxia_NN and_CC inflammation_NN has_VBZ previously_RB been_VBN reported_VBN to_TO
        increase_VB iNOS_NN expression_NN [_NN 23_CD ]_NN ._. Thus_RB ,_, the_DT increased_VBN iNOS_NN
        reported_VBD previously_RB may_MD be_VB due_JJ to_TO the_DT combination_NN of_IN
        hypoxia_NN and_CC inflammation_NN [_NN 23_CD ]_NN ._. Others_NNS have_VBP also_RB reported_VBN
        that_DT lung_NN iNOS_NN protein_NN was_VBD detectable_JJ only_RB after_IN
        lipopolysaccharide_NN administration_NN [_NN 24_CD ]_NN ._.
        The_DT iNOS_NN promoter_NN contains_VBZ a_DT hypoxia_NN responsive_JJ element_NN ,_,
        and_CC the_DT increase_NN in_IN iNOS_NN transcription_NN in_IN hypoxia_NN may_MD be_VB
        due_JJ to_TO the_DT transcription_NN factor_NN hypoxia-inducible_JJ factor-_NN 1_CD α_NN
        [_NN 25_CD ,_, 26_CD ,_, 27_CD ]_NN ._. Additionally_RB ,_, recent_JJ studies_NNS also_RB suggest_VBP
        that_IN alterations_NNS in_IN redox_NN state_NN during_IN hypoxia_NN may_MD also_RB
        increase_VB iNOS_NN expression_NN ,_, similar_JJ to_TO eNOS_NN ,_, by_IN activation_NN of_IN
        redox_NN sensitive_JJ nuclear_JJ factor-κ_JJ B_NNP or_CC activator_NN protein-_NN 1_CD [_NN
        28_CD ,_, 29_CD ]_NN ._. It_PRP is_VBZ not_RB known_VBN whether_IN hypoxia_NN interferes_VBZ with_IN
        translation_NN or_CC degradation_NN of_IN iNOS_NN protein_NN ._. In_IN support_NN of_IN
        our_PRP$ current_JJ finding_NN ,_, however_RB ,_, immunohistochemical_JJ
        localization_NN of_IN iNOS_NN to_TO the_DT airway_NN did_VBD not_RB change_VB following_VBG
        hypoxia_NN ._. We_PRP have_VBP recently_RB reported_VBN that_IN mice_NNS deficient_NN in_IN
        iNOS_NN do_VBP not_RB have_VB increased_VBN pulmonary_JJ vasoreactivity_NN ,_,
        suggesting_VBG that_IN lung-derived_JJ iNOS_NN is_VBZ not_RB an_DT important_JJ
        modulator_NN of_IN acute_JJ pulmonary_JJ vascular_NN reactivity_NN [_NN 10_CD ]_NN ._.
        Mice_NNS deficient_NN in_IN iNOS_NN do_VBP have_VBP a_DT slight_JJ increase_NN in_IN right_JJ
        ventricular_NN pressure_NN ,_, however_RB ,_, suggesting_VBG that_DT iNOS_NN ,_,
        especially_RB in_IN the_DT upper_JJ airway_NN ,_, may_MD contribute_VB to_TO
        modulation_NN of_IN chronic_JJ pulmonary_JJ vascular_NN tone_NN [_NN 10_CD ]_NN ._. Thus_RB ,_,
        the_DT importance_NN of_IN iNOS_NN in_IN hypoxic_JJ pulmonary_JJ hypertension_NN
        remains_VBZ uncertain_JJ ._.
        In_IN rat_NN lungs_NNS ,_, nNOS_NN expression_NN was_VBD increased_VBN following_VBG
        hypoxia_NN [_NN 4_CD ]_NN ,_, but_CC we_PRP did_VBD not_RB find_VB an_DT increase_NN in_IN lung_NN nNOS_NN
        in_IN mice_NNS following_VBG hypoxia_NN ._. Increased_VBN nNOS_NN has_VBZ been_VBN
        suggested_VBN as_IN a_DT compensatory_JJ vasodilator_NN in_IN the_DT cerebral_JJ and_CC
        coronary_JJ circulation_NN of_IN eNOS-deficient_JJ mice_NNS ,_, but_CC its_PRP$ role_NN
        in_IN the_DT pulmonary_JJ circulation_NN is_VBZ unknown_JJ [_NN 8_CD ,_, 30_CD ]_NN ._. However_RB ,_,
        we_PRP previously_RB demonstrated_VBD [_NN 10_CD ]_NN that_DT nNOS_NN does_VBZ not_RB appear_VB
        to_TO play_VB a_DT role_NN in_IN modulating_VBG tone_NN in_IN the_DT pulmonary_JJ
        circulation_NN ._.
        Although_IN we_PRP did_VBD not_RB look_VB at_IN the_DT expression_NN of_IN NOS_NNP in_IN
        other_JJ rat_NN vascular_NN beds_NNS following_VBG hypoxia_NN ,_, other_JJ reports_NNS
        suggest_VBP that_IN the_DT increase_NN in_IN NOS_NNP following_VBG hypoxia_NN may_MD be_VB
        species_NNS and_CC tissue_NN specific_JJ ._. Previous_JJ studies_NNS of_IN NOS_NNP
        expression_NN in_IN systemic_JJ and_CC pulmonary_JJ endothelial_NN cells_NNS from_IN
        different_JJ species_NNS in_IN cultures_NNS [_NN 31_CD ,_, 32_CD ,_, 33_CD ,_, 34_CD ,_, 35_CD ,_, 36_CD ,_, 37_CD ]_NN
        have_VBP yielded_VBN conflicting_JJ results_NNS ._. Recently_RB ,_, Toporsian_NNP 
        et_CC al_NN ._. [_NN 38_CD ]_NN reported_VBD 
        in_IN vivo_NN downregulation_NN of_IN eNOS_NN mRNA_NN
        and_CC protein_NN levels_NNS in_IN the_DT aorta_NN of_IN rats_NNS following_VBG prolonged_JJ
        hypoxia_NN ,_, which_WDT correlated_JJ with_IN impaired_VBN
        endothelium-dependent_JJ vasorelaxation_NN ,_, whereas_IN there_EX was_VBD an_DT
        increase_NN in_IN eNOS_NN protein_NN levels_NNS in_IN the_DT lungs_NNS ._. Conversely_RB ,_,
        eNOS_NN levels_NNS were_VBD increased_VBN in_IN hypoxic_JJ uterine_NN ,_, but_CC not_RB
        femoral_NN or_CC renal_JJ arteries_NNS of_IN pregnant_JJ sheep_NN [_NN 39_CD ]_NN ._.
        Whether_IN increased_VBN NOS_NNP expression_NN leads_VBZ to_TO increased_VBN
        production_NN of_IN NO_DT 
        in_IN vivo_NN is_VBZ controversial_JJ [_NN 40_CD ]_NN ._. In_IN
        piglets_NNS 
        in_IN vivo_NN ,_, acute_JJ hypoxia_NN caused_VBN
        decreased_VBD exhaled_VBD NO_DT and_CC decreased_VBD aortic_JJ and_CC pulmonary_JJ
        arterial_NN plasma_NN nitrite_NN levels_NNS [_NN 41_CD ]_NN ._. Following_VBG chronic_JJ
        hypoxia_NN in_IN rats_NNS ,_, Sato_NNP 
        et_CC al_NN ._. [_NN 42_CD ]_NN found_VBD that_DT plasma_NN NO_DT
        metabolite_NN levels_NNS were_VBD markedly_RB increased_VBN compared_VBN with_IN
        normoxic_JJ controls_NNS when_WRB animals_NNS were_VBD exposed_VBN to_TO 21_CD %_NN O_NNP 
        2_CD ,_, but_CC were_VBD not_RB increased_VBN when_WRB rats_NNS
        were_VBD breathing_VBG 10_CD %_NN O_NNP 
        2_CD ._. This_DT suggests_VBZ that_DT hypoxia_NN inhibited_VBD
        NO_DT production_NN despite_IN the_DT increase_NN in_IN NOS_NNP expression_NN ._. There_EX
        are_VBP several_JJ proposed_VBN mechanisms_NNS for_IN the_DT discordance_NN between_IN
        NO_DT production_NN and_CC increased_VBN NOS_NNP expression_NN 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN ,_, including_VBG impaired_VBN arginine_NN
        uptake_NN [_NN 43_CD ]_NN ,_, decreased_VBD heat_NN shock_NN protein-_NN 90_CD levels_NNS [_NN 44_CD ]_NN ,_,
        and_CC decreased_VBD O_NNP 
        2_CD tension_NN [_NN 42_CD ,_, 40_CD ]_NN ._. In_IN agreement_NN with_IN
        previous_JJ studies_NNS ,_, the_DT plasma_NN NO_DT metabolite_NN content_NN in_IN the_DT
        present_JJ study_NN was_VBD minimally_RB elevated_VBD in_IN the_DT hypoxic_JJ group_NN ._.
        Although_IN we_PRP attempted_VBD to_TO keep_VB the_DT mice_NNS continuously_RB
        hypoxic_JJ ,_, a_DT relatively_RB brief_JJ period_NN of_IN reoxygenation_NN might_MD
        account_VB for_IN the_DT slight_JJ increase_NN in_IN plasma_NN NO_DT metabolites_NNS
        seen_VBN in_IN the_DT hypoxic_JJ animals_NNS ,_, which_WDT is_VBZ consistent_JJ with_IN the_DT
        observations_NNS of_IN Sato_NNP 
        et_CC al_NN ._. [_NN 42_CD ]_NN ._. Because_IN the_DT systemic_JJ
        and_CC pulmonary_JJ vasculatures_NNS can_MD both_DT contribute_VB to_TO plasma_NN NO_DT
        metabolite_NN levels_NNS ,_, if_IN NOS_NNP was_VBD downregulated_JJ in_IN the_DT systemic_JJ
        circulation_NN as_IN suggested_VBN by_IN Toporsian_NNP 
        et_CC al_NN ._. [_NN 38_CD ]_NN ,_, then_RB the_DT lack_NN of_IN
        increased_VBD NO_DT metabolites_NNS could_MD also_RB be_VB due_JJ to_TO decreased_VBD NOS_NNP
        activity_NN in_IN the_DT systemic_JJ circulation_NN ._. However_RB ,_, those_DT
        investigators_NNS did_VBD not_RB observe_VB any_DT difference_NN in_IN plasma_NN NO_DT
        metabolites_NNS in_IN normoxic_JJ versus_CC hypoxic_JJ rats_NNS in_IN which_WDT aortic_JJ
        NOS_NNP was_VBD downregulated_JJ ,_, but_CC did_VBD observe_VB a_DT decrease_NN in_IN
        acetylcholine-stimulated_JJ NO_DT release_NN from_IN aortic_JJ rings_NNS ._. The_DT
        pattern_NN of_IN NOS_NNP expression_NN in_IN vascular_NN beds_NNS other_JJ than_IN the_DT
        lung_NN following_VBG hypoxia_NN in_IN mice_NNS is_VBZ presently_RB unknown_JJ ._.
      
      
        Conclusion_NNP
        In_IN summary_NN ,_, we_PRP identified_VBD a_DT unique_JJ pattern_NN of_IN NOS_NNP
        upregulation_NN in_IN the_DT murine_NN lung_NN with_IN severe_JJ hypoxia-induced_JJ
        pulmonary_JJ hypertension_NN ,_, which_WDT may_MD be_VB important_JJ when_WRB
        considering_VBG studies_NNS using_VBG NOS-deficient_NNP mice_NNS ._. The_DT present_JJ
        study_NN also_RB suggests_VBZ that_DT exposure_NN of_IN neonatal_NN mice_NNS to_TO
        hypoxia_NN may_MD lead_VB to_TO more_RBR severe_JJ pulmonary_JJ hypertension_NN than_IN
        that_DT observed_VBD in_IN mature_VBP mice_NNS exposed_VBN to_TO hypoxia_NN ,_, and_CC this_DT
        warrants_NNS further_JJ study_NN ._.
      
      
        Abbreviations_NNP
        eNOS_NN =_SYM endothelial_NN nitric_JJ oxide_NN synthase_NN ;_: iNOS_NN =_SYM
        inducible_JJ nitric_JJ oxide_NN synthase_NN ;_: nNOS_NN =_SYM neuronal_NN nitric_JJ
        oxide_NN synthase_NN ;_: NO_DT =_SYM nitric_JJ oxide_NN ;_: NOS_NNP =_SYM nitric_JJ oxide_NN
        synthase_NN ;_: PBS_NNP =_SYM phosphate-buffered_JJ saline_NN ;_: PCR_NNP =_SYM polymerase_NN
        chain_NN reaction_NN ;_: RIPA_NNP =_SYM radioimmunoprecipitation_NN assay_NN ;_: RVsP_NNP
        =_SYM right_JJ ventricular_NN systolic_JJ pressure_NN ._.
      
    
  
